Publications

  • Random Mutagenesis of Human Serine Racemase Reveals Residues Important for the Enzymatic Activity.

    Authors: H E. Hoffman, J Jirásková, M Zvelebil, J Konvalinka.

    Collect. Czech. Chem. Commun. 2010, Vol. 75, No. 1, pp. 59–79

  • In vitro and in vivo characterization of molecular interactions between calmodulin, ezrin/radixin/moesin (ERM) and L-selectin.

    Authors: Killock DJ, Parsons M, Zarrouk M, Ameer-Beg SM, Ridley AJ, Haskard DO, Zvelebil M, Ivetic A.

    J Biol Chem. (2009) Jan 7.

  • PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

    Authors: Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS.

    Clin Cancer Res. 2009 Apr 1;15(7):2269-80.

  • Recombinant human serine racemase: enzymologic characterization and comparison with its mouse ortholog.

    Authors: Hoffman H. E, Jiraskova J, Ingr M., Zvelebil M., & Konvalinka J.

    Protein Expr Purif (2009) 63, 62 - 67

  • The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.

    Authors: Banerjee S, Zvelebil M, Furet P, Mueller-Vieira U, Evans DB, Dowsett M, Martin LA.

    Cancer Res. 2009 Jun 1;69(11):4716-23.

  • A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia.

    Authors: Datta, S. R., McQuillin, A., Rizig, M., Blaveri, E., Thirumalai, S., Kalsi, G., Lawrence, J., Bass, N. J., Puri, V., Choudhury, K., Pimm, J., Crombie, C., Fraser, G., Walker, N., Curtis, D., Zvelebil, M., Pereira, A., Kandaswamy, R., St Clair, D., & Gurling, H. M.

    Mol Psychiatry (2008) Dec 2

  • IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis.

    Authors: Gyrd-Hansen, M., Darding, M., Miasari, M., Santoro, M. M., Zender, L., Xue, W., Tenev, T., da Fonseca, P. C., Zvelebil, M., Bujnicki, J. M., Lowe, S., Silke, J., & Meier, P.

    Nat Cell Biol (2008) 10, 1309 - 1317

  • Inactivation of effector caspases through nondegradative polyubiquitylation.

    Authors: Ditzel, M., Broemer, M., Tenev, T., Bolduc, C., Lee, T. V., Rigbolt, K. T., Elliott, R., Zvelebil, M., Blagoev, B., Bergmann, A., & Meier, P.

    Mol Cell (2008) 32, 540 - 553

  • MoKCa Database - Mutations of Kinases in Cancer

    Authors: Chris Richardson, Q. G., Costas Mitsopoulous, Marketa Zvelebil, Laurence Pearl, Frances Pearl

    Nucl. Acids Res (2008) gkn832

  • Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.

    Authors: Reynolds, C. H., Garwood, C. J., Wray, S., Price, C., Kellie, S., Perera, T., Zvelebil, M., Yang, A., Sheppard, P. W., Varndell, I. M., Hanger, D. P., & Anderton, B. H.

    J Biol Chem (2008) 283, 18177-86

  • Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.

    Authors: Zvelebil, M. J., Waterfield, M. D., & Shuttleworth, S. J.

    Arch Biochem Biophys (2008) 477, 404-10

  • The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer.

    Authors: Folkes, A. J. et al.

    J Med Chem (2008) 51, 5522 - 5532

  • Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate.

    Authors: Kendrick, H., Regan, J. L., Magnay, F. A., Grigoriadis, A., Mitsopoulos, C., Zvelebil, M., & Smalley, M. J.

    BMC Genomics (2008) 9, 591

  • A model of directional selection applied to the evolution of drug resistance in HIV-1

    Authors: Seoighe C, Ketwaroo F, Pillay V, Scheffler K, Wood N, Duffet R, Zvelebil M, Martinson N, McIntyre J, Morris L and Hide W.

    Molecular Biology and Evolution (2007) 24, 1025-1031.

  • Exploring the specificity of the PI3K family inhibitor LY294002.

    Authors: Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD.

    Biochem J. (2007) 404, 15-21.

  • Gene and protein expression profiling of human ovarian cancer cells treated with the HSP90 inhibitor 17-allylamino-17-demethoxy geldanamycin (17AAG)

    Authors: Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman J, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M and Workman P.

    Cancer Research (2007) 67, 3239-53.

  • Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.

    Authors: Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny.

    Science (2007) 13, 239-242.

  • Understanding Bioinformatics (book)

    Authors: Zvelebil MJ & Baum JO

    Garland Publishing Inc,US; (2007) ISBN 0815340249.

  • FLIGHT: database and tools for the integration and cross-correlation of large-scale RNAi phenotypic datasets.

    Authors: Sims D, Bursteinas B, Gao Q, Zvelebil M, Baum B.

    N.A.R (2006) 34, D479-D483.

  • iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53.

    Authors: Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T & Lu X.

    Nature Genetics (2006) 38: 1133-1141